Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	2,020	2,007	2,670	1,919	2,487	2,671
Other Revenue	4.7	4.7	7.33	3.42	4.54	4.5
Revenue	2,025	2,012	2,677	1,922	2,491	2,675
Revenue Growth (YoY)	-18.39%	-24.86%	39.27%	-22.84%	-6.88%	37.15%
Cost of Revenue	462.4	440.4	520.26	390.89	440.36	402.12
Gross Profit	1,562	1,571	2,157	1,531	2,051	2,273
Selling, General & Admin	596.17	633.15	881.19	787.89	838.78	729.46
Research & Development	191.15	198.45	240.09	245.38	253.91	173.77
Other Operating Expenses	34.72	32.17	37.29	24.61	33.72	39.56
Operating Expenses	823.15	862.83	1,159	1,048	1,124	949.55
Operating Income	739.05	708.59	997.98	482.98	926.66	1,324
Interest Expense	-51.63	-53.51	-63.71	-54.33	-36.04	-8.91
Interest & Investment Income	70.31	67.95	73.09	87.96	63.79	56.5
Currency Exchange Gain (Loss)	-2.17	-2.17	0.78	1.22	1.07	-0.81
Other Non Operating Income (Expenses)	0.8	2.01	-1.73	-2.12	-0.5	-5.34
EBT Excluding Unusual Items	756.36	722.86	1,006	515.71	954.97	1,365
Impairment of Goodwill	-	-	-5.2	-25.61	-6.26	-
Gain (Loss) on Sale of Investments	-3.32	0.01	1.02	-	-0.01	0.01
Gain (Loss) on Sale of Assets	1.96	-0.08	3.64	6.72	0.86	0.98
Asset Writedown	-61.12	-53.59	-1.04	-1.46	-1.61	-1.15
Other Unusual Items	1.13	-9.08	2.13	25.66	68.85	42.14
Pretax Income	695.01	660.13	1,007	521.02	1,017	1,407
Income Tax Expense	130.87	128.46	192.78	95.3	135.86	211.38
Earnings From Continuing Operations	564.14	531.67	814.19	425.72	880.95	1,196
Minority Interest in Earnings	0.41	1.15	6.01	10.77	8.62	0.97
Net Income	564.55	532.82	820.2	436.49	889.56	1,197
Net Income to Common	564.55	532.82	820.2	436.49	889.56	1,197
Net Income Growth	-22.05%	-35.04%	87.91%	-50.93%	-25.67%	36.74%
Shares Outstanding (Basic)	764	772	781	794	794	803
Shares Outstanding (Diluted)	764	772	781	794	794	803
Shares Change (YoY)	-2.52%	-1.14%	-1.57%	-0.08%	-1.12%	-0.89%
EPS (Basic)	0.74	0.69	1.05	0.55	1.12	1.49
EPS (Diluted)	0.74	0.69	1.05	0.55	1.12	1.49
EPS Growth	-20.03%	-34.29%	90.91%	-50.89%	-24.83%	37.96%
Free Cash Flow	545.35	548.63	815.85	669.49	407.91	712
Free Cash Flow Per Share	0.71	0.71	1.04	0.84	0.51	0.89
Dividend Per Share	0.520	0.520	0.800	0.400	0.670	0.900
Dividend Growth	-35.00%	-35.00%	100.00%	-40.30%	-25.56%	36.36%
Gross Margin	77.16%	78.11%	80.57%	79.67%	82.33%	84.97%
Operating Margin	36.50%	35.22%	37.28%	25.12%	37.19%	49.48%
Profit Margin	27.88%	26.48%	30.64%	22.71%	35.70%	44.73%
Free Cash Flow Margin	26.94%	27.27%	30.47%	34.83%	16.37%	26.61%
EBITDA	854.53	825.76	1,122	573.43	995.72	1,373
EBITDA Margin	42.21%	41.05%	41.90%	29.83%	39.97%	51.32%
D&A For EBITDA	115.48	117.16	123.92	90.44	69.07	49.25
EBIT	739.05	708.59	997.98	482.98	926.66	1,324
EBIT Margin	36.50%	35.22%	37.28%	25.12%	37.19%	49.48%
Effective Tax Rate	18.83%	19.46%	19.14%	18.29%	13.36%	15.02%
Revenue as Reported	2,025	2,012	2,677	1,922	2,491	2,675

Source: S&P Global Market Intelligence. Standard template. Financial Sources.